CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Lieberman LA, Zeng W, Singh C, Wang W, Otipoby KL, Loh C, Plavina T, Gorelik L, Ransohoff RM, Cahir-McFarland E Neurology. 2015 Dec 30. PMID: 26718566. Abstract CommentRecommendBookmarkWatch